Rapamycin

The formulation of Rapamycin for the prevention of cancer progression and recurrence.

210 876 1357
info@rapamycinholdings.com
  • Home
  • ABOUT US
    • Management Team
    • Advisors
  • Our Technology
    • What is eRAPA™?
    • The Research
    • Prevention of Cancer Progression and Recurrence
    • Cognitive Dysfunction
  • CONTACT US
  • NEWS
  • INVESTORS
  • home-erapa-banner

    What is eRapa™?

    eRapa™ inhibits the progression and recurrence of cancer. Research has shown Rapamycin rejuvenates the immune system exhausted by age and cancer exposure and helps attack early stage bladder and prostate cancer cells.
  • home-research-banner

    The Research

    eRapa™ was developed at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio, and is the only pharmaceutical agent tested thus far to demonstrate significantly increased health span and lifespan in rodent models.
  • home-prevention-banner

    Prevention of Cancer Progression and Recurrence

    Early evidence shows a potential for eRapa™ to prevent the progression and recurrence of prostate and bladder cancer, meeting a significant unmet need in the marketplace.
  • home-alzheimers-banner

    Cognitive Dysfunction

    Scientists at the Barshop Institute have demonstrated that orally administered eRapa™ can prevent the development of Alzheimer’s pathologies in mice.
  • home-news-banner

    eRapa™ News

    Over the past decade, (Rapamycin) has shown promise as a drug that not only can extend life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, but also postpone the effects of normal aging.

WHAT IS eRAPA™?

What is eRAPA™?

eRapa™ inhibits the progression and recurrence of cancer. Research has shown eRapa rejuvenates the immune system exhausted by age and cancer exposure. Click here to read more.

THE RESEARCH

The Research

eRapa™ was developed at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio, and is the only pharmaceutical agent tested thus far to demonstrate significantly increased health span and lifespan in rodent models. Click here to read more.

CANCER PREVENTION

Prevention of Cancer Progression and Recurrence

Early evidence shows a potential for eRapa™ to prevent the progression of prostate cancer and Familial Adenomatous Polyposis, a precursor to colon cancer, meeting a significant unmet need in the marketplace. Click here to read more.

COGNITIVE DYSFUNCTION

Cognitive Dysfunction

Scientists at the Barshop Institute have demonstrated that orally administered eRapa™ can prevent the development of Alzheimer’s pathologies in mice. Click here to read more.

eRAPA NEWS

eRAPA™ NEWS

Over the past decade, Rapamycin has shown promise as a drug that not only can extend life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, but also postpone the effects of normal aging. Click here to read more.

  • HOME
  • ABOUT US
  • OUR TECHNOLOGY
  • CONTACT US
  • NEWS

INVESTORS
info@rapamycinholdings.com
210-876-1357

Copyright © 2022 Rapamycin Holdings, Inc. All rights reserved. Click here to view Terms of Use.